TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17239709
Drug: Simvastatin +
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin + Pioglitazone (Combination)
Study: 15278753
Drug: Oral enzyme‐rutosid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enzyme‐rutosid combination (ERC)
Study: 7525170
Drug: Insulin-treated adult
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated adult diabetic patients
Study: 7525170
Drug: Non-insulin-treated adult
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin-treated adult diabetic patients
Study: 6387568
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% indomethacin
Study: 29701043
Drug: Clomiphene (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (oral administration for 5 days starting from the 5th day of menstruation or medicine-withdrawal bleeding)
Study: 12482789
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose lisinopril (32.5 or 35 mg)
Study: 12482789
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lisinopril (2.5 or 5 mg)
Study: 12482789
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of beta blockers or antiarrhythmic agents (mainly amiodarone)
Study: 12482789
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting nitrates and previous use of angiotensin converting enzyme inhibitors
Study: 8691702
Drug: Orchiectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orchiectomy plus diethylstilbestrol diphosphate plus combination chemotherapy with cisplatin and methotrexate
Study: 1379883
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of risperidone daily
Study: 6381185
Drug: Cimetidine 2.4
Normalized name: cimetidine 2.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 2.4 g/day
Study: 11759022
Drug: Alcoholic gels
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic gels
Study: 9781721
Drug: cA2 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: cA2 (300 mg single dose)
Study: 7878557
Drug: nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nedocromil sodium (4 mg) four times daily
Study: 3226339
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of oestradiol valerate (E2V)
Study: 17139218
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (short-segment posterior stabilization)
Study: 14514368
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment (Group B)
Study: 11192518
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate supplementation (1 mg/kg per day)
Study: 8472516
Drug: Tablets (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (600 mg of ST‐679)
Study: 8472516
Drug: Envelopes (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Envelopes (600 mg of ST‐679)
Study: 2433901
Drug: Dextran 40
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40 (500 ml on admission and on days 1 and 2; 250 ml on days 4 and 6)
Study: 24987174
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil 25 mg, administered eight hourly for 24 hours before surgery (N = 20)
Study: 24987174
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil 25 mg
Study: 22570428
Drug: Orlistat 60
Normalized name: orlistat 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 60 mg taken up to 3 times daily
Study: 19890257
Drug: Beta-adrenoceptor antagonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoceptor antagonist propranolol
Study: 18806024
Drug: Intranasal remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal remifentanil (4 mcg/kg)
Study: 15664480
Drug: Amoxicillin/clavulanate (2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (2000/125 mg), given twice daily
Study: 15664480
Drug: Conventional amoxicillin/clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amoxicillin/clavulanate formulations (control)
Study: 15664480
Drug: Amoxicillin/clavulanate (2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (2000/125 mg) for PRSP-infected patients
Study: 12092689
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (twice daily insulin injections plus an annual insulin infusion)
Study: 7479201
Drug: Cefotaxime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime plus metronidazole (1-g intravenous dose of cefotaxime plus 500-mg oral dose of metronidazole)
Study: 7479201
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intravenous doses every 6 hours)
Study: 7479201
Drug: Ampicillin-sulbactam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (3 g intravenous doses every 6 hours)
Study: 20471706
Drug: Digoxin treatment
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin treatment
Study: 6803946
Drug: Oral cholecystography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecystography
Study: 28817412
Drug: Bodyflow (BF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bodyflow (BF) therapy
Study: 28817412
Drug: Deep oscillation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep oscillation (DO) therapy
Study: 27712462
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy with PRF and 1% ALN gel (group 3)
Study: 27712462
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy alone (group 1)
Study: 27712462
Drug: Access therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access therapy with PRF (group 2)
Study: 17364153
Drug: Laparoscopic transabdominal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic transabdominal preperitoneal patch (TAPP) procedure
Study: 15383196
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 frovatriptan
Study: 15383196
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 placebo
Study: 10103339
Drug: Abacavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir monotherapy (4 mg/kg every 12 hours for 6 weeks, then 8 mg/kg every 12 hours for 6 weeks)
Study: 10103339
Drug: Abacavir in
Normalized name: Product containing abacavir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir in combination with another antiretroviral agent (8 mg/kg every 12 hours for 12 weeks)
Study: 10708287
Drug: Abacavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir monotherapy
Study: 2108254
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of MgSO4, B complex, and vitamin C in Ringer's lactate solution
Study: 2108254
Drug: EDTA after
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA after initial placebo treatment
Study: 28910196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Alpinia galanga (E-AG-01) with caffeine
Study: 22801247
Drug: Triple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple oral therapy (metformin, glyburide, and pioglitazone)
Study: 19592630
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and metformin
Study: 22801247
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and metformin (initial therapy)
Study: 22801247
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (triple oral therapy and insulin/metformin)
Study: 21359582
Drug: Insulin-based treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-based treatment
Study: 9541446
Drug: Fucithalmic single
Normalized name: Fucithalmic
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fucithalmic single unit dose eye drops
Study: 24148616
Drug: Oral 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 3% saline
Study: 23062548
Drug: rHFSC (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHFSC (recombinant human hyaluronidase-facilitated subcutaneous rehydration)
Study: 23062548
Drug: IV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV (intravenous rehydration)
Study: 15275765
Drug: Oxazepam 15
Normalized name: oxazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 15 mg (active placebo)
Study: 11420167
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aprotinin (20,000 IU/kg as pretreatment followed by 7500 IU/kg for 6 h)
Study: 12959274
Drug: BRL 35135
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 35135 8 mg
Study: 12959274
Drug: Nadolol 20
Normalized name: nadolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 20 mg (N20) + BRL 35135 8 mg
Study: 3549173
Drug: Bitolterol mesylate
Normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bitolterol mesylate 1.0 mg
Study: 3549173
Drug: Bitolterol mesylate
Normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bitolterol mesylate 0.5 mg to 3.0 mg
Study: 3549173
Drug: Bitolterol mesylate
Normalized name: Bitolterol Mesylate
DrugBank: Bitolterol (DB00901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bitolterol mesylate >1.0 mg
Study: 27089542
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A (BTX) treatment with calf muscle injections every 6 months if needed
Study: 27089542
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CO) consisting of firm shoes, night splints, home stretching program, and physiotherapy
Study: 27089542
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A (BTX) treatment
Study: 12111069
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CO)
Study: 24225356
Drug: 6-month lipid-based
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month lipid-based nutrient supplement (LNS) providing 108 kcal and other nutrients including vitamin A, vitamin B-12, iron, and zinc at ≥80% of the recommended amounts
Study: 24225356
Drug: 3-month lipid-based
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month lipid-based nutrient supplement (LNS)
Study: 20684825
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment after PCI
Study: 14629243
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 mg per day, with increments to a maximum of 100 mg per day)
Study: 7795149
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g fish-oil concentrate per day
Study: 2029123
Drug: Pediazole (ES)
Normalized name: erythromycin ethylsuccinate / sulfisoxazole Oral Suspension [Pediazole]
DrugBank: Acetyl sulfisoxazole (DB14033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediazole (ES) - 50 mg/kg + 150 mg/kg sulfamide, given in three divided doses for ten days
Study: 2029123
Drug: Cefaclor -
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor - 40-50 mg/kg, given in three divided doses for ten days
Study: 30372084
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg IR tablet
Study: 20589148
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment for thromboembolic complications
Study: 20589148
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment for haemorrhagic complications
Study: 17342693
Drug: Washout period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout period after treatment
Study: 14665555
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of gelatin colloid solution intravenously before surgery
Study: 14665555
Drug: Conventional i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional i.v. fluid regime with a crystalloid solution (saline)
Study: 11703374
Drug: HAART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART with plasma HIV-1 RNA suppressed to below 500 copies/ml (group 1)
Study: 7703514
Drug: Ileo-rectal anastomosis
Normalized name: POUCH,ILEO DISPOSABLE GRICKS #GR4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ileo-rectal anastomosis (IRA)
Study: 29365294
Drug: Solanezumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solanezumab (400 mg, intravenously every 4 weeks for 76 weeks)
Study: 23965396
Drug: BMS-927711 75
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-927711 75 mg
Study: 23965396
Drug: BMS-927711 150
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-927711 150 mg
Study: 23965396
Drug: BMS-927711 300
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-927711 300 mg
Study: 23965396
Drug: BMS-927711 (25-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-927711 (25-600 mg)
Study: 20400912
Drug: Pantoprazole 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 1.2 mg/kg/day for 4 weeks
Study: 17910747
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg plus hydrochlorothiazide 12.5 mg (T/HCTZ)
Study: 16260435
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy (MST) for 6 months
Study: 10525755
Drug: Venlafaxine 18.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 18.75 mg
Study: 10525755
Drug: Paroxetine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 5 mg
Study: 1771173
Drug: Aspartame (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (500 mg)
Study: 1771173
Drug: Sucrose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (100 g)
Study: 7067996
Drug: Self-administered, mailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered, mailed questionnaires
Study: 31693974
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IL-6, IL-8, ST2, sTNFR2, IL-12, and TNF-α
Study: 24629994
Drug: Monovalent human-bovine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent human-bovine rotavirus vaccine (116E)
Study: 19702643
Drug: Total Therapy
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Therapy 3 (TT3) with added bortezomib
Study: 15151172
Drug: TMZ MR
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ MR 35 mg b.i.d.
Study: 15151172
Drug: TMZ IR
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ IR 20 mg t.i.d.
Study: 15151172
Drug: TMZ MR
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ MR in dogs and pigs (multiple dose simulations)
Study: 11579646
Drug: Ketanserin gel
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin gel (2%)
Study: 11579646
Drug: Clioquinol cream
Normalized name: Clioquinol Cream
DrugBank: Clioquinol (DB04815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clioquinol cream and/or Lassar paste
Study: 9675961
Drug: Pr IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pr IR 150 mg x 3
Study: 9675961
Drug: Pr SR
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pr SR 325 mg x 2
Study: 9675961
Drug: Pr SR
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pr SR 225 mg x 2
Study: 8017357
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms, twice daily for 2 months)
Study: 2872793
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine (5 to 30 mg)
Study: 2872793
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 to 80 mg)
Study: 22588154
Drug: CT screening
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT screening with five annual low-dose CT scans
Study: 20718170
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg orally
Study: 20718170
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg intravenously
Study: 18572758
Drug: Gas-powered, needle-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas-powered, needle-free injection device (NFID)
Study: 18569233
Drug: Dose-response slope
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response slope
Study: 9084344
Drug: Piracetam 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam 4.8 g/day with intensive language therapy for 6 weeks
Study: 9084344
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with intensive language therapy for 6 weeks
Study: 8251285
Drug: Edrophonium 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.1, 0.2, 0.4, or 1 mg kg‐1
Study: 8251285
Drug: Neostigmine 0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.005, 0.01, 0.02, or 0.05 mg kg‐1
Study: 31256599
Drug: Conjugated Linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated Linoleic Acid (CLA) supplementation (3000 mg daily in 3 doses)
Study: 30029523
Drug: High-dose 'Benifuuki'
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 'Benifuuki' extract (676 mg of catechins)
Study: 30029523
Drug: Low-dose 'Benifuuki'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 'Benifuuki' extract (322 mg of catechins)
Study: 22404221
Drug: Swallowing exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing exercise (placing a milk bolus of 0.05‐0.2 mL on the tongue)
Study: 15482044
Drug: Alcohol behavioral
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol behavioral couples therapy (ABCT)
Study: 15482044
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (ABCT, RP/ABCT, AA/ABCT)
Study: 21236721
Drug: High-dose/short-term hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose/short-term hepatitis B vaccination schedules
Study: 21236721
Drug: New immunogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New immunogenic formulations of hepatitis B vaccine
Study: 9596305
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg twice a day for 3 days
Study: 9596305
Drug: Salmeterol 100
Normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 100 microg twice a day for 3 days
Study: 7829764
Drug: TRH tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH tests administered before, during, and after ECT
Study: 18403102
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with ISO 0.1 microg/mL
Study: 16788315
Drug: Standard haemostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard haemostatic replacement therapy (placebo)
Study: 10955434
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oestradiol implants
Study: 9925060
Drug: 3 mg/d
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/d of beclomethasone dipropionate (BDP)
Study: 7572574
Drug: rTPA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA alone (100 mg in 3 hours)
Study: 2180474
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with oxprenolol or oxprenolol plus dihydralazine
Study: 2180474
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with oxprenolol
Study: 30225529
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day for 8 weeks
Study: 28358815
Drug: Azathioprine 50mg
Normalized name: AZATHIOPRINE 50MG TAB
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine 50mg for 24, 36 or 48 weeks with steroid treatment (oral prednisolone for 20 weeks)
Study: 28358815
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (oral prednisolone for 20 weeks)
Study: 28358815
Drug: Azathioprine treatment
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine treatment for 48 weeks